Display Settings:

Format

Send to:

Choose Destination
    Vaccine. 2011 Jun 24;29(29-30):4735-8. Epub 2011 May 12.

    Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children.

    Source

    Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Rama 4 Road, Pratumwan, Bangkok 10330, Thailand.

    Abstract

    The immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine (Epaxal®) was evaluated in a group of 45 Thai children with human immunodeficiency virus (HIV) infection, age 2-16 years. Vaccines were administered at 0 and 6 months. Anti-HAV antibody titers were measured at baseline (before injection) 1 and 7 months after primary vaccination. The prevalence of HAV protective antibody in 45 Thai HIV-infected children was 13.6%. The seroprotection rate was 71% at 1 month and 100% at 7 months. The booster dose increased geometric mean concentration (GMC) from 106.5 mIU/ml to 3486.1 mIU/ml. Higher CD4 lymphocyte counts at enrollment was a predictive factor for HAV antibody response. Both doses of Epaxal® were well tolerated. These preliminary data suggest that a pediatric dose of Epaxal® is an effective hepatitis A vaccine for HIV-infected children and should be considered for implementation on a larger scale in the pediatric HIV population.

    Copyright © 2011 Elsevier Ltd. All rights reserved.

    PMID:
    21570433
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk